Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants

Chiappini, Elenaa; Galli, Luisaa; Giaquinto, Carlob; Ene, Luminitac; Goetghebuer, Tessad; Judd, Alie; Lisi, Catiusciaf; Malyuta, Ruslang; Noguera-Julian, Antonih; Ramos, Jose Tomasi; Rojo-Conejo, Pabloj; Rudin, Christophk; Tookey, Patl; de Martino, Maurizioa; Thorne, Clairel; for the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord

doi: 10.1097/QAD.0b013e32835cffb1
Epidemiology and Social

Objectives: To evaluate use of combination neonatal prophylaxis (CNP) in infants at high risk for mother-to-child transmission (MTCT) of HIV in Europe and investigate whether CNP is more effective in preventing MTCT than single drug neonatal prophylaxis (SNP).

Design: Individual patient-data meta-analysis across eight observational studies.

Methods: Factors associated with CNP receipt and with MTCT were explored by logistic regression using data from nonbreastfed infants, born between 1996 and 2010 and at high risk for MTCT.

Results: In 5285 mother–infant pairs, 1463 (27.7%) had no antenatal or intrapartum antiretroviral prophylaxis, 915 (17.3%) had only intrapartum prophylaxis and 2907 (55.0%) mothers had detectable delivery viral load despite receiving antenatal antiretroviral therapy. Any neonatal prophylaxis was administered to 4623 (87.5%) infants altogether; 1105 (23.9%) received CNP. Factors significantly associated with the receipt of CNP were later calendar birth year, no elective caesarean section, maternal CD4 cell count less than 200 cells/μl, maternal delivery viral load more than 1000 copies/ml, no antenatal antiretroviral therapy, receipt of intrapartum single-dose nevirapine and cohort. After adjustment, absence of neonatal prophylaxis was associated with higher risk of MTCT compared to neonatal prophylaxis [adjusted odds ratio (aOR) 2.29; 95% confidence interval (95% CI) 1.46–2.59; P < 0.0001]. Further, there was no association between CNP and MTCT compared to SNP (aOR 1.41; 95% CI 0.97–2.5; P = 0.07).

Conclusion: In this European population, CNP use is increasing and associated with presence of MTCT risk factors. The finding of no observed difference in MTCT risk between one drug and CNP may reflect residual confounding or the fact that CNP may be effective only in a subgroup of infants rather than the whole population of high-risk infants.

Author Information

aDepartment of Sciences for Woman and Child's Health, University of Florence, Anna Meyer Children's University Hospital, Florence

bUniversity of Padua, Italy

cVictor Babes Hospital, Bucharest, Romania

dHôpital St Pierre, Brussels, Belgium

eMedical Research Council Clinical Trials Unit, London, UK

fDepartment of Statistics, University of Florence, Italy

gPerinatal Prevention of AIDS Initiative, Odessa, Ukraine

hHospital Sant Joan de Déu-Universitat de Barcelona, Barcelona

iHospital Universitario de Getafe, Madrid

jHospital 12 de Octubre, Madrid, Spain

kUniversität Basel, Switzerland

lUniversity College London, UK.

Correspondence to Elena Chiappini, Department of Science for Woman and Child's Health, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy. E-mail:

Received 3 August, 2012

Revised 13 November, 2012

Accepted 23 November, 2012

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

© 2013 Lippincott Williams & Wilkins, Inc.